Sandoz Names Board Ahead Of Novartis Spinoff
Preparatory Work Begins In June; Formal Constitution Of Board To Follow By Year End
As Sandoz moves closer to being spun off from parent company Novartis, the generics and biosimilars firm has revealed the structure and membership of its board under chair Gilbert Ghostine.
You may also be interested in...
Sandoz Makes Major Moves To Bolster Biosimilars Ahead Of Spinoff
Sandoz has made further preparations to bolster its biosimilars business ahead of its spinoff from parent company Novartis, announcing a development and manufacturing deal with Evotec at the same time as unveiling a further investment in its Holzkirchen site to transform it into a biotech development hub.
Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal
Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.